Objective: This study aimed to evaluate the relation of Lactate dehydrogenase (LDH) levels with stage of the disease and it role in monitoring tumor response to therapy in lymphoma patients.
Differences between lymphoma and control groups were assessed using the Student's t test. Regression and correlation analyses between variables were performed by calculating Pearson's correlation coefficients (r). P values of > 0.05 were considered not significant.
Results:
Analysis of LDH concentration shows that the serum LDH level was significantly higher in untreated children with both hodgkin's and non hodgkin's lymphomas compared to control group (p<0.001).
Furthermore, this level increased during disease growth time. When HL and NHL patients were separately studied against the control group the difference was significantly high, more remarkably in NHL patients. On the other hand, the mean serum LDH level in NHL patients was significantly higher than that of HL The survival rate for five years after the treatment was 93.75%. The analysis of LDH levels of diagnosed patients against their survival rates, showed that those with higher LDH levels were exposed to early relapse of their disease. However, there was no significant correlation between LDH level before the treatment with survival rate.
Liver and kidney function tests and blood cell count in total HD and NHL patients were compared to control. The levels of albumin and hemoglobin were significantly lower in lymphoma patients compared to control (p<0.001) (Figure.4) . However, the total WBC count and Erythrocyte sedimentation rate were significantly higher in lymphoma patients compared to control (p<0.001)( Figure.5 ).
Pearson correlation analysis of serum LDH among HL and NHL patient groups showed no correlation between serum LDH levels and biochemical or hematological parameters (Table. 2).
Discussion
Among biochemical parameters, lactate dehydrogenase (LDH) represents a very valuable enzyme in patients with malignant lymphomas. The serum level has been considered as very important in the evaluation of disease extension in non-Hodgkin's lymphomas (NHL) and Hodgkin's disease (HD) 13 .
In this study, we have analazed the relation between serum LDH level, stage and response to treatment on 33 patients with HL and 32 patients with NHL. The LDH level was significantly elevated in lymphoma patients compared to control. This finding agrees with that, reported by other investigators 14, 15 .This intense LDH level observed in patients during cancerous conditions may be the result of high glycolytic rate 16 . In fact, the high glycolytic rate is important for rapidly proliferating cancers 24, 25 .
Indeed, mechanisms for energy production involved in cell duplication require a high LDH cell content and renewal of NAD resynthesis, in support of a continuing glycolysis. For a given tumor bulk LDH production is conceived as being proportional to its metabolic and proliferative activity. Accordingly, high LDH production suggests either large tumor bulk or a fast proliferation in a smaller tumor, and this could explain an aggressive course and a poorer response to therapy 26, 27 .
In addition, the tumor cells may produce LDH enzyme to respond to the increase of lactic acid, 
Conclusion
Lactate dehydrogenase (LDH) plays an important role in tumor initiation and maintenance since its ability to function in anaerobic metabolism helps cancer cells grow even after their rapid proliferation leads to low-oxygen conditions in the tumor microenvironment. The elevated serum LDH could be used to select patients who will benefit from more intensified treatment.
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